(3R,5R)-3,5-二羟基-7-[(1S,2R,3S,8S,8aR)-3-羟基-2-甲基-8-{[(2S)-2-甲基丁酰]氧代}-1,2,3,7,8,8a-六氢萘-1-基]庚酸 | 81131-74-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 中文名称: (3R,5R)-3,5-二羟基-7-[(1S,2R,3S,8S,8aR)-3-羟基-2-甲基-8-{[(2S)-2-甲基丁酰]氧代}-1,2,3,7,8,8a-六氢萘-1-基]庚酸
• 英文名称: SQ 31906
• 英文别名: 3-alpha-hydroxy-pravastatin；3'α-isopravastatin；3α-isopravastatin；SQ 31,906；C-6 epimer of pravastatin；RMS-416；3'alpha-Isopravastatin；(3R,5R)-7-[(1S,2R,3S,8S,8aR)-3-hydroxy-2-methyl-8-[(2S)-2-methylbutanoyl]oxy-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid
• CAS: 81131-74-0
• 化学式: C₂₃H₃₆O₇
• 分子量: 424.535
• InChiKey: HIZIJHNJVQOXLO-YMUQFYNDSA-N

物化性质

• 沸点：
  640.3±55.0 °C(Predicted)
• 密度：
  1.21±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.74
• 拓扑面积：
  124
• 氢给体数：
  4
• 氢受体数：
  7

反应信息

• 作为产物：
  描述：

  pravastatin sodium salt 在 水 作用下， 反应 504000.0h， 生成 普伐他汀类酯 、 (betaR,deltaR,1S,2S)-1,2-二氢-beta,delta,6-三羟基-2-甲基-1-萘庚酸钠盐 、 (3R,5R)-3,5-二羟基-7-[(1S,2R,3S,8S,8aR)-3-羟基-2-甲基-8-{[(2S)-2-甲基丁酰]氧代}-1,2,3,7,8,8a-六氢萘-1-基]庚酸
  参考文献：
  名称：

  Selection of solid dosage form composition through drug–excipient compatibility testing

  摘要：

  A drug-excipient compatibility screening model was developed by which potential stability problems due to interactions of drug substances with excipients in solid dosage forms can be predicted. The model involved storing drug-excipient blends with 20% added water in closed glass vials at 50 degrees C and analyzing them after 1 and 3 weeks for chemical and physical stability. The total weight of drug-excipient blend in a vial was usually kept at about 200 mg. The amount of drug substance in a blend was determined on the basis of the expected drug-to-excipient ratio in the final formulation. Potential roles of several key factors, such as the chemical nature of the excipient, drug-to-excipient ratio, moisture, microenvironmental pH of the drug-excipient mixture, temperature, and light, on dosage farm stability could he identified by using the model. Certain physical changes, such as polymorphic conversion or change from crystalline to amorphous form, that could occur in drug-excipient mixtures were also studied. Selection of dosage form composition by using this model at the outset of a drug development program would lead to reduction of "surprise" problems during long-term stability testing of drug products.

  DOI：

  10.1021/js980434g

文献信息

• Nigovic, Biljana; Vegar, Ivana, Croatica Chemica Acta, 2008, vol. 81, # 4, p. 615 - 622
  作者：Nigovic, Biljana、Vegar, Ivana

  DOI：——

  日期：——
• Selection of solid dosage form composition through drug–excipient compatibility testing
  作者：Abu T.M. Serajuddin、Ajit B. Thakur、Rabin N. Ghoshal、Michael G. Fakes、Sunanda A. Ranadive、Kenneth R. Morris、Sailesh A. Varia

  DOI：10.1021/js980434g

  日期：1999.7

  A drug-excipient compatibility screening model was developed by which potential stability problems due to interactions of drug substances with excipients in solid dosage forms can be predicted. The model involved storing drug-excipient blends with 20% added water in closed glass vials at 50 degrees C and analyzing them after 1 and 3 weeks for chemical and physical stability. The total weight of drug-excipient blend in a vial was usually kept at about 200 mg. The amount of drug substance in a blend was determined on the basis of the expected drug-to-excipient ratio in the final formulation. Potential roles of several key factors, such as the chemical nature of the excipient, drug-to-excipient ratio, moisture, microenvironmental pH of the drug-excipient mixture, temperature, and light, on dosage farm stability could he identified by using the model. Certain physical changes, such as polymorphic conversion or change from crystalline to amorphous form, that could occur in drug-excipient mixtures were also studied. Selection of dosage form composition by using this model at the outset of a drug development program would lead to reduction of "surprise" problems during long-term stability testing of drug products.